Two decades of orphan product development
Two decades of orphan product development
复制标题
DOI：
10.1038/nrd919
复制
发表时间：
2002-10-01
影响因子：
120.1
通讯作者：
Moses, M
中科院分区：
文献类型：
--
作者：
Haffner, ME;Whitley, J;Moses, M
在过去的20年里，《孤儿药法案》（ODA）的激励措施，美国食品和药物管理局校外临床赠款的最大单一来源，对公共卫生产生了重大影响。官方发展援助的激励措施促进了许多创新生物技术产品的开发，随着我们对人类基因组的理解不断发展，预计药物基因组学将导致更多的“孤儿病”的确定。
Over the past 20 years, incentives of the Orphan Drug Act (ODA), the largest single source of extramural clinical grants at the US Food and Drug Administration, have had a substantial impact on public health. ODA incentives have contributed to the development of many innovative biotechnology products, and as our understanding of the human genome evolves, it is anticipated that pharmacogenomics will result in the identification of more 'orphan diseases'.